Welcoming - Award ceremony Fernandez-Cruz Memorial
Memorial Lecture, Awardee: Clifford H. Lane
PANEL 1. Adolfo García-Sastre. Cellular and Molecular...
PANEL 2. S. Valor - B. Regueiro - P. Rosenstock - M. A. Rodgers
PANEL 3. A. Osinusi - P. Horby - A. M. Henao
PANEL 4. Nathan Roth. Manipulation of the im..
PANEL 5. E. Fernández-Cruz - Adolfo García-Sastre - Luis Enjuanes - Gert Shepert
Adjourn. President Fernández-Cruz Foundation, Arturo Fernández-Cruz
Welcoming - Award ceremony Fernandez-Cruz Memorial
Memorial Lecture, Awardee: Clifford H. Lane
Learnings from the pandemic CoVID-19: development of strategies “INSIGHT COVID-19 Trials” for prevention and treatment against pandemic virus SARS-CoV-2.
Dr. Clifford H. Lane, Clinical Director Division of Clinical Research. National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH). USA.
PANEL 1. Adolfo García-Sastre. Cellular and Molecular...
Cellular and Molecular Pathogenesis of Emerging RNA Viruses. Chairs:Vicente EstradaJefe de Servicio de Infecciosas del Hospital Universitario Clínico San Carlos y Dr. Eduardo Fernández-Cruz, Profesor Jefe de Servicio de Inmunología, Hospital General Universitario Gregorio Marañón, Madrid
Research on the interaction of SARS-CoV-2 and the host. Adolfo García-Sastre, Director of the Global Health and Emerging Pathogens Institute. Icahn School of Medicine. Mount Sinai. New York. USA
PANEL 2. S. Valor - B. Regueiro - P. Rosenstock - M. A. Rodgers
Translational and Clinical State Of The Art of Laboratory testing for detecting antibody immunity to Coronavirus SARS-CoV-2. Chairs: Dr. Santiago Valor, Dr. Eduardo Fernández-Cruz y Dr. Rafael Cantón, Jefe de Servicio de Microbiología. Hospital Universitario Ramón y Cajal, Madrid
Introduction. Santiago Valor. Director Médico SYNLAB
Specific antibodies to protein S from SARS-CoV-2. Benito Regueiro. Catedrático de Microbiología. U de Santiago. DIASORIN
IgA Antibodies in the diagnosis of SARS-CoV-2. Philip Rosenstock, Producto manager infection diagnostics. Lubeck Germany. EUROIMMUN
SARS-CoV-2 diagnostics: solutions for a spectrum of testing needs and settings.Mary A. Rodgers (Principal Scientific Infectious Diseases, Abbott Laboratories USA)
PANEL 3. A. Osinusi - P. Horby - A. M. Henao
Treatments “sick care”, The field in perspective. Chairs: Dr. Vicente Estrada y Dr. Arturo Fernández-Cruz
The search for effective antiviral therapy/Evaluation of Benefit of Remdesivir treatment for COVID-19.Anu Osinusi, Executive Director, Clinical Research-Virology, GILEAD. Foster City, USA
Corticoid therapy to debate. Peter Horby, Professor of Emerging Infectious Diseases and Global Health. Founding of the Oxford University Clinical (Oxford/UK)
Outcomes related to Covid 19 clinical trials using combination therapy. Ana María Henao. World Health Organisation (WHO). Ginebra.
PANEL 4. Nathan Roth. Manipulation of the im..
The 2020 inevitable debate: Manipulation of the immune systems as an important component in the potential therapeutic control and prevention of Covid-19. Chairs:Dr. Eduardo Fernández-Cruz, Adolfo Garcia-Sastre
Development of anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin by CoVig-19 Alliance.Nathan Roth, Vice President PPD, R&D. CSL Behring. King of Prussia, USA
PANEL 5. E. Fernández-Cruz - Adolfo García-Sastre - Luis Enjuanes - Gert Shepert
Development of VACCINES and generation of protective Immune Responses to coronavirus COVID-19. Chair: Dr. Luis Enjuanes,Co-chairs: Adolfo García-Sastre y Eduardo Fernández-Cruz
Development of an effective protective community (herd) immunity to the pandemic virus SARS-CoV-2.Eduardo Fernández-Cruz, Profesor Jefe de Servicio de Inmunología, Hospital General Universitario Gregorio Marañón. Madrid. Spain
New challenges in the development of vaccines for emerging viruses.Adolfo García-Sastre, Director of the Global Health and Emerging Pathogens Institute. Icahn School of Medicine. Mount Sinai. New York. USA
Development of human RNA replicons as vaccines for pathogenic human coronaviruses.Luis Enjuanes, National Center of Biotechnology (CNB-CSIC), Campus Universidad Autónoma de Madrid. Spain
First results of a COVID-19 vaccine developed by Johnson & Johnson through its Janssen Pharmaceutical Companies (Janssen). Gert Shepert. Compound Development Team Leader (CDTL), Therapeutic HPV Vaccine at Crucell/JANSSEN. Utrech, Netherland
DEBATE: VACCINE DEVELOPMENT”. Coordinator: Clifford Lane
CONCLUDING REMARKS: Arturo Fernández-Cruz
Adjourn. President Fernández-Cruz Foundation, Arturo Fernández-Cruz
